Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
← catalyst calendarNCT07631637 · readout in 902 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
150estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-15 | estimated | When the study began enrolling |
| Primary completion | 2029-02-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-02-06 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions
- Drug: ALN-CIDEB
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent change from baseline in liver fat by Magnetic Resonance Imaging-derived Proton Density Fat Fraction (MRI-PDFF)
measured At week 26
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed